Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Gross Profit: 2019-2025

Historic Gross Profit for Keros Therapeutics (KROS) over the last 5 years, with Sep 2025 value amounting to $14.3 million.

  • Keros Therapeutics' Gross Profit rose 3575.77% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $246.7 million, marking a year-over-year increase of 37798.31%. This contributed to the annual value of $3.5 million for FY2024, which is 2250.99% up from last year.
  • As of Q3 2025, Keros Therapeutics' Gross Profit stood at $14.3 million, which was down 21.50% from $18.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Gross Profit registered a high of $211.2 million during Q1 2025, and its lowest value of -$1,000 during Q1 2021.
  • Over the past 3 years, Keros Therapeutics' median Gross Profit value was $388,000 (recorded in 2024), while the average stood at $27.5 million.
  • Data for Keros Therapeutics' Gross Profit shows a peak YoY spiked of 2,000,100.00% (in 2021) over the last 5 years.
  • Keros Therapeutics' Gross Profit (Quarterly) stood at $20.0 million in 2021, then spiked by 1,800,100.00% to $18.0 million in 2022, then reached $143,000 in 2023, then soared by 2,027.27% to $3.0 million in 2024, then soared by 3,575.77% to $14.3 million in 2025.
  • Its Gross Profit stands at $14.3 million for Q3 2025, versus $18.2 million for Q2 2025 and $211.2 million for Q1 2025.